TY-9591
- Generic Name
- TY-9591
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
Phase 2
Recruiting
- Conditions
- Brain MetastasesNSCLCEGFR Activating Mutation
- Interventions
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 420
- Registration Number
- NCT05948813
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 6
- Registration Number
- NCT05871905
- Locations
- 🇨🇳
Suzhou first people's hospital, Suzhou, Jiangsu, China
Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)
Phase 3
Recruiting
- Conditions
- EGFR Activating MutationNSCLC
- Interventions
- First Posted Date
- 2022-05-19
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 680
- Registration Number
- NCT05382728
- Locations
- 🇨🇳
Hunan Provincial Tumor Hospital, Changsha, Hunan, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath